Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma

NCT01390571 is registered in ClinicalTrials.gov with Cancer Research UK as lead sponsor.

NCT NCT01390571
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01390571 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma
Lead sponsor
Cancer Research UK
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2011
Completion date
June 20, 2017
Enrollment
34 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors